PharmaCyte defends board and strategy against Iroquois Capital; accelerates pancreatic cancer trial

PharmaCyte Biotech, Inc.

Company expects to begin Phase 2b pancreatic cancer trial immediately upon FDA lifting clinical hold, saving ~6 months.
Board plans to add capital markets experience; Iroquois has not recommended any candidate despite offer.
New executive compensation agreements tie cash and equity bonuses to achievement of corporate goals.
Company raised ~$90M in two capital raises and uplisted to Nasdaq; cash provides strategic advantage.
Company reiterates strategy will deliver higher shareholder value over time; rejects Iroquois' characterizations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.